U.S. Capital Wealth Advisors LLC Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

U.S. Capital Wealth Advisors LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.8% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 71,398 shares of the biopharmaceutical company’s stock after selling 4,373 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Gilead Sciences were worth $5,986,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Manning & Napier Advisors LLC bought a new stake in shares of Gilead Sciences in the second quarter worth approximately $25,328,000. Legal & General Group Plc grew its position in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the period. GSA Capital Partners LLP bought a new position in shares of Gilead Sciences during the 1st quarter valued at $462,000. Brookstone Capital Management boosted its stake in shares of Gilead Sciences by 751.1% in the 1st quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock worth $9,322,000 after buying an additional 112,305 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after buying an additional 33,162 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, October 9th. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a report on Monday, July 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 target price on shares of Gilead Sciences in a report on Monday, September 16th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Finally, Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday. Ten research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.85.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,847 shares of company stock valued at $3,033,340 over the last 90 days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $0.32 during mid-day trading on Wednesday, hitting $87.84. 1,252,335 shares of the company’s stock traded hands, compared to its average volume of 7,034,009. The company has a market capitalization of $109.44 billion, a P/E ratio of 244.89, a PEG ratio of 2.98 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $88.36. The company’s 50-day moving average is $81.61 and its two-hundred day moving average is $73.07. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The company had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.51%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.